CJC-1295 + Ipamorelin — Research Reference
The CJC-1295 + Ipamorelin combination is the most widely researched growth hormone stack in anecdotal research communities. It pairs two distinct classes of GH secretagogue: a GHRH (growth hormone-releasing hormone) analogue and a GHRP (growth hormone-releasing peptide), achieving dual-pathway stimulation of growth hormone release from the pituitary.
Stack Overview
| Parameter | Detail |
|---|---|
| Components | CJC-1295 (without DAC / Mod GRF 1-29) + Ipamorelin |
| Mechanism | GHRH receptor agonism (CJC-1295) + ghrelin receptor agonism (Ipamorelin) |
| Primary reported goal | Growth hormone optimisation, body composition, recovery |
| Category | Growth Hormone |
Research context: Both components have been studied independently in published research. The combination is supported by mechanistic rationale — simultaneous stimulation of two distinct receptors involved in GH release is proposed to produce a synergistic GH pulse greater than either compound alone. Neither compound is approved for use in healthy individuals.
Components
| Component | Class | Primary Mechanism | Standard Research Form |
|---|---|---|---|
| CJC-1295 (no-DAC / Mod GRF 1-29) | GHRH analogue | GHRH receptor agonist; stimulates pituitary to release GH | 100–300 mcg per injection |
| Ipamorelin | GHRP / ghrelin mimetic | Ghrelin receptor (GHSR) agonist; stimulates GH release; suppresses somatostatin | 100–300 mcg per injection |
CJC-1295 without DAC (Mod GRF 1-29) is the form predominantly described in combination with Ipamorelin. CJC-1295 with DAC (Drug Affinity Complex) has a much longer half-life (~7 days) and a different dosing profile — it is generally not the form combined with Ipamorelin in the protocols described here.
For individual compound profiles, see:
Commonly Reported Protocol
The following information represents commonly reported research ranges from anecdotal accounts. These are not medical recommendations.
Standard Injection Protocol
Both compounds are typically co-administered subcutaneously at the same time, in separate syringes (drawn individually and injected at the same subcutaneous site or adjacent sites):
| Parameter | Commonly Reported Range |
|---|---|
| CJC-1295 (no-DAC) dose | 100–200 mcg per injection |
| Ipamorelin dose | 100–200 mcg per injection |
| Frequency | 2–3 injections per day |
| Timing | Fasted state; most commonly upon waking and before sleep |
| Cycle duration | 12–24 weeks commonly reported |
Timing rationale: GH secretagogues are reported to produce larger GH pulses in a fasted, low-insulin state. Morning (fasted) and pre-sleep timing aligns with natural GH pulsatility patterns — the largest endogenous GH pulse occurs shortly after sleep onset. Anecdotal research accounts commonly describe 2 daily injections (morning and evening) as a practical starting point.
Mixing note: CJC-1295 and Ipamorelin can be reconstituted separately and drawn into a single syringe for one injection — this approach is widely described in anecdotal accounts and is reported to be compatible (the peptides do not interact adversely when combined).
Reported Synergies
The combination rationale rests on two complementary mechanisms:
1. Dual receptor stimulation: CJC-1295 (no-DAC) acts on the GHRH receptor, amplifying the natural GH pulse. Ipamorelin acts on the ghrelin/GHSR receptor through a distinct pathway. Animal research has reported that combining GHRH analogues with ghrelin receptor agonists produces GH pulses larger than either compound alone — a synergistic rather than merely additive effect.
2. Somatostatin suppression: Ipamorelin is proposed to suppress somatostatin (growth hormone-inhibiting hormone) activity, reducing the brake on pituitary GH release. CJC-1295 simultaneously increases the stimulatory drive. The combination addresses both the accelerator and the brake of GH secretion.
3. Ipamorelin’s selectivity advantage: Ipamorelin is notable for its selectivity — it stimulates GH release with minimal effect on cortisol, prolactin, or ACTH secretion compared to older GHRPs (GHRP-2, GHRP-6). This selectivity is considered advantageous in research contexts where minimal off-target hormonal stimulation is preferred.
Reported Effects
The following effects have been reported in anecdotal research accounts and, to varying extents, in published research on the individual components. This list reflects the research landscape, not confirmed outcomes.
Growth Hormone and IGF-1 Elevation
Both components act to increase pulsatile GH release from the pituitary. Elevated GH drives liver production of insulin-like growth factor 1 (IGF-1), the primary downstream mediator of GH’s anabolic and metabolic effects. Published studies on individual GHRH analogues and GHRPs have confirmed GH and IGF-1 elevation in humans. The combination is expected to produce amplified GH pulses based on mechanistic synergy.
Body Composition
Anecdotal research accounts consistently describe improved body composition with extended use (12+ weeks): reported reduction in body fat (particularly visceral fat), preservation or modest increase in lean mass. These effects are proposed to be IGF-1-mediated and are consistent with the known actions of GH axis stimulation.
Sleep Quality
Improvement in sleep quality is among the most frequently described effects in anecdotal accounts, often noted within the first 1–2 weeks of use. The pre-sleep injection timing (amplifying the natural sleep-onset GH pulse) is considered to contribute to this effect.
Recovery
Anecdotal research accounts describe improved recovery from training and injury. GH is known to play a role in soft tissue repair and collagen synthesis, and improved recovery is consistent with GH axis stimulation.
Skin and Connective Tissue
Some anecdotal accounts describe improvements in skin quality, hair, and connective tissue with extended use — effects consistent with IGF-1 elevation and collagen synthesis stimulation.
Reported Side Effects
Reported side effects in research and anecdotal accounts include the following.
| Side Effect | Frequency Reported |
|---|---|
| Injection site redness or mild pain | Common |
| Water retention / mild oedema | Occasionally reported (GH effect) |
| Fatigue (initial days) | Occasionally reported |
| Headache | Occasionally reported |
| Tingling or numbness (hands/feet) | Occasionally reported |
| Vivid dreams | Occasionally reported (pre-sleep dosing) |
| IGF-1 elevation (expected pharmacological effect) | Universal at therapeutic doses |
IGF-1 elevation: Sustained IGF-1 elevation is the intended pharmacological consequence of GH stimulation. At supraphysiological levels, elevated IGF-1 carries theoretical concerns around cell proliferation. Clinical data on GH secretagogues has not demonstrated cancer risk at the doses studied, but this consideration is noted in the research literature.
Insulin sensitivity: GH can impair insulin sensitivity transiently. Anecdotal accounts more commonly describe this effect at higher doses. Monitoring of fasting glucose is described in research accounts for extended cycles.
Research Context
Neither CJC-1295 (without DAC) nor Ipamorelin has received approval for use in healthy adults for body composition or performance purposes. Both are research compounds. The combination protocol is entirely anecdotal in healthy human populations — clinical research on GH secretagogues has focused primarily on GH-deficient or elderly populations.
The stack is not prohibited by WADA for out-of-competition research, but GH and its secretagogues are prohibited in competition.
Frequently Asked Questions
Why use Mod GRF 1-29 (no-DAC) rather than CJC-1295 with DAC? CJC-1295 without DAC has a short half-life (~30 minutes), producing discrete GH pulses that mimic the natural pulsatile pattern of GH release. CJC-1295 with DAC has a half-life of approximately 7 days, producing sustained, relatively constant GHRH receptor stimulation — a pattern that differs substantially from physiological GH secretion. The pulse-mimicking pattern of no-DAC is generally preferred in anecdotal research accounts when combining with Ipamorelin, as Ipamorelin itself is also short-acting and the combined injection produces a defined, synergistic GH pulse.
How long before results are noticeable? Anecdotal research accounts most frequently describe improved sleep quality within the first 1–2 weeks. Body composition effects — fat reduction and lean mass changes — are described as requiring sustained use of at least 12 weeks to become apparent, consistent with the slow, steady nature of GH-mediated metabolic changes.
Can this stack be used simultaneously with BPC-157 or TB-500? There is no known pharmacological interaction between GH secretagogues and healing peptides like BPC-157 or TB-500. Anecdotal research accounts frequently describe combining the two categories — GH secretagogues for systemic optimisation and healing peptides for localised recovery. See the Wolverine Stack → for the BPC-157 + TB-500 combination reference.
Is the 3-injection-per-day protocol significantly better than 2? Anecdotal accounts describe both 2x and 3x daily dosing; the marginal benefit of the third injection is debated. Most accounts consider 2x daily (morning and pre-sleep) sufficient for the primary goals of sleep optimisation, body composition, and recovery.
Related Stacks
- Wolverine — BPC-157 + TB-500 — Healing and recovery focus
- GLOW — BPC-157 + TB-500 + GHK-Cu — Regenerative skin and tissue stack
- KLOW — BPC-157 + TB-500 + GHK-Cu + KPV — Comprehensive healing stack